D. Ross Camidge, MD, PhD

D. Ross Camidge, MD, PhD, is a professor of medicine-medical oncology, and director of the Thoracic Oncology Clinical Program and Clinical Research Program at the University of Colorado Cancer Center – Anschutz Medical Campus.

Articles

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

April 15th 2024

Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.

Camidge and Rabinowitz Reflect on Finding Strength and Inspiration on Both Sides of a Cancer Diagnosis

April 4th 2024

Drs Camidge and Rabinowitz discuss the balance between professional and personal life that Rabinowitz navigated when he was diagnosed with lung cancer.

Camidge and Lewis Discuss the Perspective of Being Both a Patient and Physician

March 14th 2024

Drs Camidge and Lewis discuss how Dr Lewis’ MEN-1 diagnosis has affected his professional life and the importance of seeking patient perspectives.

Dr Camidge on the Rationale for the TRUST-II Trial in ROS1+ NSCLC

September 20th 2023

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations.

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

January 24th 2019

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Dr. Camidge on Mechanisms of Resistance to TKIs in NSCLC

November 27th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

November 10th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC

October 31st 2018

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

Dr. Camidge on the KEYNOTE-024 Trial in NSCLC

August 23rd 2018

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

November 1st 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

Dr. Camidge on the Unmet Needs for Lung Cancer

October 25th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with lung cancer.

Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

October 16th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

Dr. Camidge on MET as a Target in Lung Cancer

April 23rd 2015

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

October 31st 2014

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Dr. Camidge Discusses Next-Generation Sequencing

October 24th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

Dr. Camidge on AP26113 in Advanced Malignancies

October 7th 2013

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

Dr. Camidge on a Phase I Study With AZD9291 in NSCLC

September 30th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

June 13th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

Dr. Camidge on Targeted Therapies in Adjuvant NSCLC

May 7th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

Dr. Camidge on the Evolution of Clinical Cancer Research

October 11th 2012

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the ever changing and evolving world of clinical cancer research.